Proqr hopes to usherin a new ophthalmic therapy
The group’s antisense project is the only game in town for Usher syndrome, but its latest trial is not a slam-dunk.
A busy year ahead for Parkinson’s disease
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
New Genmab/Abbvie tie-up rings old bells
Followers of Nordic Nanovector and Oxford Biomedica, among others, will pay close attention to an early focus of yesterday’s deal.
What to look for in upcoming Covid-19 trial readouts
Industry-sponsored clinical studies against the new coronavirus have proliferated, as have their designs and efficacy measures.
Upcoming events – Avadel takes on Jazz and Axovant awaits early results
Data will soon show whether Avadel’s FT218 is more convenient than Jazz’s Xyrem, while Axovant will be looking for a dose response with its Parkinson’s gene therapy.
Plenty of choice remains for buyers of gene therapy
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
Axovant reaps the rewards from its gene therapy refocus
Axovant is the latest company to benefit from excitement over gene therapy data in small numbers of patients.
Sanofi does a spring clean
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
